Xuan Wang
Hebei Medical University(CN)Army Medical University(CN)Dalian Medical University(CN)Peking University(CN)Peking University Cancer Hospital(CN)Second Affiliated Hospital of Chongqing Medical University(CN)Second Hospital of Hebei Medical University(CN)Baylor Scott & White Health(US)Chongqing Medical University(CN)
Publications by Year
Research Areas
Cutaneous Melanoma Detection and Management, Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, CAR-T cell therapy research, Immunotherapy and Immune Responses
Most-Cited Works
- → Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients(2019)186 cited
- → Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial(2019)165 cited
- → Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy(2017)115 cited
- → Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma(2019)108 cited
- → <p>Comparison of the Value of Neutrophil to High-Density Lipoprotein Cholesterol Ratio and Lymphocyte to High-Density Lipoprotein Cholesterol Ratio for Predicting Metabolic Syndrome Among a Population in the Southern Coast of China</p>(2020)74 cited